CABA Earnings Date: Nov 9, 2026 (Estimated) — Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CABA's next earnings date?
Cabaletta Bio, Inc. (CABA) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.33 on revenue of $1.7M.
How did CABA do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Cabaletta Bio, Inc. posted EPS of -$0.34 versus the -$0.37 estimate, a beat of 2.9%. Revenue was $0 against a $1.7M estimate. The stock's 1-day post-earnings move was -4.9%.
How much does CABA stock move after earnings?
CABA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.37 | -0.34 | +2.86% | $0 | ✅ Beat | -4.91% | +8.77% | -4.21% |
| 2026-05-14 | Q1 2026 | -0.39 | -0.39 | +0.00% | $0 | ➖ Inline | +0.56% | -4.18% | -16.16% |
| 2026-03-23 | Q4 2025 | -0.46 | -0.40 | +13.04% | $0 | ✅ Beat | -4.08% | -8.84% | +6.46% |
| 2025-11-10 | Q3 2025 | -0.47 | -0.44 | +6.38% | $0 | ✅ Beat | -4.71% | -9.41% | -1.96% |
| 2025-03-31 | Q4 2024 | -0.64 | -0.65 | -1.56% | $0 | ❌ Miss | -10.65% | -28.39% | -17.42% |
| 2024-11-14 | Q3 2024 | -0.60 | -0.62 | -3.33% | $0 | ❌ Miss | -5.74% | -43.64% | -29.68% |
| 2024-05-15 | Q1 2024 | -0.44 | -0.51 | -15.91% | $0 | ❌ Miss | +13.00% | +8.55% | +11.84% |
| 2024-03-21 | Q4 2023 | -0.39 | -0.46 | -17.95% | $0 | ❌ Miss | -3.20% | -5.35% | -26.38% |
Showing last 8 quarters.